NewsBenzingaImmutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Immutep Reports Encouraging Survival Data From Phase 2 Cancer Trial Benzinga 2026.11.11 16:27 (GMT+0) Open on Benzinga Other news AI Stocks, Neoclouds Rebound From SoftBank Bump, Get CoreWeave Lift JP Morgan Maintains Overweight on NexGen Energy, Lowers Price Target to $12 JP Morgan Maintains Underweight on MARA Holdings, Lowers Price Target to $9 $1000 Invested In AutoZone 20 Years Ago Would Be Worth This Much Today JP Morgan Maintains Neutral on Leonardo DRS, Lowers Price Target to $48 On Holding Posts Slight Q3 Beat, Analysts Expect Growth To Accelerate In Q4
